biologic

Alymsys

bevacizumab-maly

Loss of exclusivity—loss of exclusivity
CompanyAmneal Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameAlymsys
Active ingredientbevacizumab-maly
Strength400MG/16ML (25MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.